Immunic earnings date
Immunic (10V) Q3 2024 Earnings Report
DE:10V Q3 2024 EPS Results
- Actual EPS
- -EUR 2.19
- Consensus EPS
- -EUR 1.99
- Beat/Miss
- Missed by -EUR 0.20
- One Year Ago EPS
- -EUR 4.65
DE:10V Q3 2024 Revenue Results
- Actual Revenue
- EUR 0
- Expected Revenue
- EUR 5,471.881
- Beat/Miss
- Missed by -EUR 5,471.881
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2024
- Date
- 11/07/2024
- Time
- Before Open
- Conference Call
- Thursday, November 7, 2024
Immunic's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2024 Earnings Call Audio
Q3 2024 Earnings Slide Deck
Q3 2024 Earnings Call Summary
The earnings call presented significant positive developments, including strengthened leadership, progress in key clinical trials, and potential market impact of vidofludimus calcium. However, challenges such as increased R&D expenses and net losses were also noted. The sentiment leans slightly positive due to the promising clinical trial results and potential market opportunities.
During the Q3 2024 earnings call for Immunic, the company provided several key metrics and guidance concerning its financial status and clinical development programs. Immunic ended the quarter with $59.1 million in cash, which is expected to fund operations into Q3 2025. R&D expenses were reported at $21.4 million for the quarter, reflecting an increase from the previous year due to costs associated with clinical trials, offset by savings from deprioritized programs. The net loss for the quarter was approximately $24.4 million or $0.24 per share. Significant clinical milestones were also discussed, including the anticipated top-line data from the Phase II CALLIPER trial in progressive MS expected in April 2025, and the continuation of the Phase III ENSURE trials in relapsing MS, with the first trial completion expected by Q2 2026. The company also highlighted ongoing interest from pharmaceutical companies for potential partnerships, driven by the innovative profile and market potential of their lead asset, vidofludimus calcium.
- Strengthened Management and BoardAppointment of Jason Tardio as President and COO and Simona Skerjanec to the Board, enhancing the team's expertise in drug commercialization and development.
- Positive Phase III ENSURE Program Interim AnalysisThe interim analysis of the Phase III ENSURE program for vidofludimus calcium in relapsing MS showed it is not futile, allowing trials to continue as planned.
- Phase II CALLIPER Trial ProgressOngoing Phase II CALLIPER trial of vidofludimus calcium in progressive MS, with top-line data expected in April 2025.
- New Clinical Trial InitiationEnrollment of the first patient in a Phase II clinical trial of vidofludimus calcium in post-COVID syndrome.
- Financial Position$59.1 million in cash expected to fund operations into the third quarter of 2025.
- Potential Market ImpactVidofludimus calcium is projected to reach peak sales of USD 2 billion to USD 6 billion, transforming the oral disease-modifying therapy market for MS.
DE:10V Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | -0.77- | -0.91 | ― | ― |
| Nov 13, 2026 | 2026 (Q3) | -0.72-0.90 | -1.19 | 23.85% (+0.28) | |
| Aug 11, 2026 | 2026 (Q2) | -1.06-0.73 | -1.82 | 60.00% (+1.09) | |
| May 13, 2026 | 2026 (Q1) | -0.63-0.98 | -2.28 | 56.80% (+1.30) | |
| Feb 26, 2026 | 2025 (Q4) | -0.82-0.91 | -2.28 | 60.00% (+1.37) | |
| Nov 13, 2025 | 2025 (Q3) | -1.31-1.19 | -2.19 | 45.83% (+1.00) | |
| Aug 07, 2025 | 2025 (Q2) | -1.44-1.82 | -1.92 | 4.76% (+0.09) | |
| May 08, 2025 | 2025 (Q1) | -0.22- | -0.27 | ― | |
| Feb 20, 2025 | 2024 (Q4) | -0.21- | -0.44 | ― | |
| Nov 07, 2024 | 2024 (Q3) | -1.99-2.19 | -4.65 | 52.94% (+2.46) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


